MASSAs – Melatonin Agonist and Selective Serotonin Antagonist

This is a new type of treatment, and to date there is not much information available on the net.

In the treatment of moderate to severe depression associated with a new drug a novel mode of action is available. This has the melatonergic antidepressant mode of action of the neurotransmitter melatonin, which is responsible for the fine adjustment of biological rhythms.

This “specific melatonin agonist and serotonin antagonist” is its effect directly the melatonergic binding sites (receptors) of the suprachiasmatic nucleus, i.e, the internal clock of man into force. At the same time, it inhibits certain uptake sites for serotonin in the nerve cells, thereby releasing a greater proportion of the neurotransmitters norepinephrine and dopamine in the brain is that the normalization of signal transmission for regulating emotional (limbic) system of the brain provide. It is assumed that the positive antidepressant properties of this drug by the interplay of these receptors arise.

The direct effect of the substance to the internal clock of the human causes a normalization of biorhythms disturbed depressed patients. It is similar to the circadian rhythm of the natural day-night rhythm. Thus helping the new antidepressant for disorders of the sleep-wake rhythm of depressed patients, without directly drowsy effect to have. Sufferers feel on the day overwhelmingly awake, refreshed and active.

The melatonergic antidepressant, in contrast to classical antidepressants less side effects. It affects weight-neutral, generally the patient experience therefore not considered drug related weight gain. Also receiving the drug with sexual function and it occur during therapy usually to no sexual dysfunction.